Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Porr, Marinomed, Andritz (26/05/2021)

30.05.2021

Porr: In the first quarter of 2021, construction group Porrs’s production output rose by 6.3% to Euro 1,002 mn. The sharpest growth was seen in Austria and in Polish infrastructure construction. Porr again generated the majority of its output on its seven home markets, which accounted for 95%. Earnings before taxes of Euro -9.4 mn were significantly higher than the same period of the previous year, climbing by Euro 16.2 mn. Earnings in the first quarter are negative due to seasonal factors and are therefore not necessarily indicative of the full year. With a record order backlog of Euro 7,920 mn, the company is optimally positioned for the future. Overall, for 2021 the Executive Board assumes production output of approximately Euro 5.3 bn to Euro 5.5 bn and a positive EBT margin of +1.3% to +1.5%.
Porr: weekly performance: 2.70%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today reported strong growth for the first quarter of 2021. Marinomed’s revenues more than doubled to Euro 2.2 mn (Q1 2020: Euro 1.0 m). The increase mainly resulted from the continued demand in the Company’s Carragelose-based virus blockers, especially in comparison to the pre-pandemic Q1 2020. Clinical data published in early 2021 confirmed Marinomed’s previous findings that Carragelose virus blocker is effective against SARS-CoV-2, reinforcing the demand for Carragelose-based products during the pandemic. Due to increased research & development (R&D) investments in the two technology platforms, Marinosolv and Carragelose, the operating result (EBIT) decreased to Euro -1.7 mn (Q1 2020: Euro -1.4 mn). For the full year the Company expects Carragelose sales to grow further but below the 2020 level. Marinomed plans a slight increase in R&D costs leading to an operating loss in fiscal 2021.
Marinomed Biotech: weekly performance: -0.40%

Andritz: International technology Group Andritz has received an order from Shanying Paper (Guangdong) to supply the approach flow-, fiber recovery-, and broke handling systems for two board production lines to its mill in Zhaoqing, Guangdong Province, China. Start-up is scheduled for the second quarter of 2022.
Andritz: weekly performance: 3.27%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (26/05/2021)


Partners









latest 21st Austria

21st Austria weekly - Porr, Marinomed, Andritz (26/05/2021)


30.05.2021, 2387 Zeichen



Porr: In the first quarter of 2021, construction group Porrs’s production output rose by 6.3% to Euro 1,002 mn. The sharpest growth was seen in Austria and in Polish infrastructure construction. Porr again generated the majority of its output on its seven home markets, which accounted for 95%. Earnings before taxes of Euro -9.4 mn were significantly higher than the same period of the previous year, climbing by Euro 16.2 mn. Earnings in the first quarter are negative due to seasonal factors and are therefore not necessarily indicative of the full year. With a record order backlog of Euro 7,920 mn, the company is optimally positioned for the future. Overall, for 2021 the Executive Board assumes production output of approximately Euro 5.3 bn to Euro 5.5 bn and a positive EBT margin of +1.3% to +1.5%.
Porr: weekly performance: 2.70%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today reported strong growth for the first quarter of 2021. Marinomed’s revenues more than doubled to Euro 2.2 mn (Q1 2020: Euro 1.0 m). The increase mainly resulted from the continued demand in the Company’s Carragelose-based virus blockers, especially in comparison to the pre-pandemic Q1 2020. Clinical data published in early 2021 confirmed Marinomed’s previous findings that Carragelose virus blocker is effective against SARS-CoV-2, reinforcing the demand for Carragelose-based products during the pandemic. Due to increased research & development (R&D) investments in the two technology platforms, Marinosolv and Carragelose, the operating result (EBIT) decreased to Euro -1.7 mn (Q1 2020: Euro -1.4 mn). For the full year the Company expects Carragelose sales to grow further but below the 2020 level. Marinomed plans a slight increase in R&D costs leading to an operating loss in fiscal 2021.
Marinomed Biotech: weekly performance: -0.40%

Andritz: International technology Group Andritz has received an order from Shanying Paper (Guangdong) to supply the approach flow-, fiber recovery-, and broke handling systems for two board production lines to its mill in Zhaoqing, Guangdong Province, China. Start-up is scheduled for the second quarter of 2022.
Andritz: weekly performance: 3.27%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (26/05/2021)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S24/21: Hugo Brock




 

Bildnachweis

Aktien auf dem Radar:AT&S, UBM, Strabag, Zumtobel, Lenzing, Agrana, Uniqa, Wolford, RBI, OMV, Porr, Palfinger, Fabasoft, Rosgix, Erste Group, Kapsch TrafficCom, Polytec Group, Wiener Privatbank, Warimpex, Frauenthal, BKS Bank Stamm, Oberbank AG Stamm, Amag, CA Immo, EuroTeleSites AG, CPI Europe AG, Österreichische Post, Semperit, Telekom Austria, Deutsche Post, Caterpillar.


Random Partner

EY
Bei EY wird alles daran gesetzt, dass die Welt besser funktioniert. Dafür steht unser Anspruch „Building a better working world“. Mit unserem umfassenden Wissen und der Qualität unserer Dienstleistungen stärken wir weltweit das Vertrauen in die Kapitalmärkte und Volkswirtschaften.

>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten